ClinicalTrials.gg

Program

Allogeneic Invariant Natural Killer T-cells agenT-797

Also written as “agenT-797” and “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”.

Its studies are mostly in Respiratory Distress Syndrome · Pneumonia · Neoplasms · Multiple Myeloma, led by 3 companies.

Furthest: phase 2, since Oct 6, 20205 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenus30 open or runningphase 1since Oct 6, 2020Oct 6, 2020none ahead
ImmunityBio10 open or runningphase 2since Mar 13, 2026Mar 13, 2026none ahead
MiNK Therapeutics11 open or runningphase 2since May 22, 2026May 22, 2026Jun 2027phase 2 · NCT07615010

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2020First study: phase 1 study in Respiratory Distress SyndromeNew to AgenusAgenus · NCT04582201 · 20 enrolled · United States
  2. Feb 3, 2021Phase 1 study in Multiple MyelomaAgenus · NCT04754100 · 13 enrolled · United States
  3. Oct 12, 2021Phase 1 study in NeoplasmsAgenus · NCT05108623 · 34 enrolled · United States
  4. Mar 13, 2026ImmunityBio’s first study: phase 2 study in Respiratory Distress SyndromeNew to ImmunityBioImmunityBio · NCT07492888
  5. May 22, 2026MiNK Therapeutics’ first study: phase 2 study in PneumoniaNew to MiNK TherapeuticsMiNK Therapeutics · NCT07615010 · 90 planned · United States, Ukraine

Ahead

  1. Jun 2027Primary completion: phase 2 study in PneumoniaMiNK Therapeutics · NCT07615010

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07615010Pneumonia · United States, Ukraine2RecruitingMiNK TherapeuticsJun 202790
NCT07492888Respiratory Distress Syndrome2WithdrawnImmunityBioNov 15, 20260
NCT05108623Neoplasms · United States1CompletedAgenusJan 2, 202434
NCT04754100Multiple Myeloma · United States1CompletedAgenusJan 13, 202313
NCT04582201Respiratory Distress Syndrome · United States1CompletedAgenusApr 23, 202320

How it is read

Names in the registry

  • “agenT-797”, 4 entries
  • “Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.